CD Capital

Qihe Biotech develops novel genome editing technologies with an emphasis on making them autonomous and programmable.

Healingovation is a med-tech company that specializes in the development and manufacturing of surgical robots, intelligent diagnosis and treatment equipment.

Greenon Biotech specializes in the research, development, production, and promotion of alternative antibiotic preparations for animals, which primarily include bacteriophages, probiotics, plant extracts, novel acid preparations, high-efficiency disinfectants, and so on.

Molbreeding is a biotechnology company specializing in molecular breeding technology for both animals and plants. It offers advanced genotyping solutions aimed at enhancing breeding processes. The firm emphasizes research and development in this field, utilizing proprietary technologies such as GenoPlexs and GenoBaits. These innovations provide customers with high capture efficiency, extensive coverage, and adaptable sample options, all while maintaining cost-effective custom services. Molbreeding's focus on molecular breeding positions it as a key player in the advancement of agricultural biotechnology.

Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in biotechnology. It specializes in antibody-based drugs that enhance immune system function, along with providing technical consultation and drug quality inspection services. By focusing on these areas, Kanova aims to help clients improve drug quality and advance the discovery of new biomedicine efficiently.

Acchrom, operating under Huapu Instrument (Beijing) Technology Co., Ltd., specializes in chromatographic separation products, offering comprehensive solutions that include equipment, consumables, software, and technical services. The company aims to establish itself as a leading national brand in chromatography by developing targeted marketing strategies and building a professional marketing network across key provinces. Acchrom's focus on the complete chromatography process enables clients to effectively analyze and separate mixtures, positioning the company as a significant player in the field.

Illumax is a company that specialises in the research and development of single-serve chemiluminescence, single-serve flow fluorescence, and laboratory automation technologies. It also offers the industry an open ecological platform for chemiluminescence and flow fluorescence.

Qihe Biotech develops novel genome editing technologies with an emphasis on making them autonomous and programmable.

Svision is a healthcare start-up that develops and produces high-end ophthalmic imaging equipment.

Better Medtech specializes in innovative solutions for urinary and pelvic floor health. The company focuses on the research and development, production, and sales of specialized medical devices aimed at addressing conditions such as benign prostatic hyperplasia, urinary incontinence, and kidney stones, as well as novel tumor therapies. By providing advanced medical technology and equipment, Better Medtech supports healthcare providers with effective instrument solutions tailored to meet the needs of patients and enhance medical care.

SprintRay is a manufacturer of 3D printers specializing in digital dentistry, aimed at enhancing the capabilities of dental professionals. Since its inception in 2014, the company has focused on creating advanced and user-friendly products that enable dentists to respond swiftly to patient needs and broaden their treatment options. SprintRay's technology offers comprehensive additive manufacturing solutions that are designed to improve the efficiency of dental practices. By making 3D printing accessible and reliable, SprintRay seeks to transform the field of dentistry and expand the applications of desktop 3D printing into other industries.

Zhejiang Xunshi Technology Co., Ltd. specializes in the development and manufacturing of 3D printers, printing consumables, and 3D scanners. The company offers a range of desktop printers tailored for specific sectors, including the MoonRay D for dental applications, MoonRay J for jewelry, and MoonRay S for educational purposes. Its industrial printer lineup features the SLA laser rapid prototyping printer, the SolarRay DLP 3D printer, and ceramic 3D printers such as the CeraRay CR-I and CeraRay TC-I. Additionally, Xunshi produces 3D architectural printers designed for contour crafting and provides photosensitive resin and photocurable wax products for dentistry, jewelry, and ceramics. The company's desktop scanners serve various applications in dental medicine, education, research, and industry. Established in 2013, Xunshi Technology is headquartered in Shaoxing, China.

Neukio Biotherapeutics specializes in developing allogenic immune cell therapies for cancer treatment. The company is dedicated to the research, development, and industrialization of immune cell drugs, particularly through its innovative iPSC-CAR-NK technology. By combining in-house innovation with collaborations with leading partners, Neukio aims to create effective therapeutic solutions for cancer patients globally. Through its efforts, the company seeks to advance the commercialization of these novel treatments, ensuring they are accessible to oncology providers and ultimately improving patient outcomes.

Acchrom, operating under Huapu Instrument (Beijing) Technology Co., Ltd., specializes in chromatographic separation products, offering comprehensive solutions that include equipment, consumables, software, and technical services. The company aims to establish itself as a leading national brand in chromatography by developing targeted marketing strategies and building a professional marketing network across key provinces. Acchrom's focus on the complete chromatography process enables clients to effectively analyze and separate mixtures, positioning the company as a significant player in the field.

Full-Life Technologies is a radiotherapeutics company focused on the research, development, production, and commercialization of radiopharmaceuticals aimed at cancer therapy. The company specializes in targeted cancer treatment, leveraging advancements in nuclear medicine to enhance clinical outcomes for patients. By prioritizing innovative radiopharmaceutical research, Full-Life Technologies aims to improve treatment results for those affected by cancer, demonstrating a commitment to delivering significant clinical impact in the field of oncology.

HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.

Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development and production of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, and metabolic disorders. The company offers a diverse range of products, including 45 innovative genetic metabolic disease screening reagents, deaf genetic testing kits, and HLA-B27 detection kits. These products aim to facilitate early detection of genetic conditions and birth defects, promoting timely intervention and disease prevention. Yingsheng Bio utilizes advanced molecular diagnostic techniques and sophisticated detection systems, contributing significantly to the fields of human genetics and public health.

Westlake Omics is a biotechnology company based in Hangzhou, Zhejiang, China, founded in 2020. It specializes in mass spectrometry-based proteomics and other Omics technologies to meet critical clinical needs. The company aims to advance precision medicine and drug research and development by utilizing artificial intelligence for high-throughput proteomic analysis of small clinical specimens. Through its innovative approach, Westlake Omics focuses on enhancing the accuracy of tumor diagnosis and developing reliable, cutting-edge products that address significant health challenges. By integrating technological advancements and multi-modal big data, the company is dedicated to making meaningful contributions to the field of clinical diagnostics.

Wancheng Gene is a single-cell gene detection platform, which is mainly used to serve the scientific research, clinical and industrial markets with a self-developed high-throughput single-cell sequencing technology platform. The existing services of Wancheng Gene include sample preparation, database sequencing, analysis, and sample processing. They can be freely combined according to customer needs, and provide peripheral services such as sample preparation training and biometric analysis.

ForQaly specializes in the development of minimally invasive ventricular assist devices designed to treat heart failure patients. The company focuses on creating therapeutic devices that enhance circulation while ensuring affordability for patients. Their products are characterized by features such as reduced trauma, high auxiliary flow, and user-friendly design, providing healthcare professionals with effective solutions for improving patient health. By combining innovation with accessibility, ForQaly aims to address the clinical needs of patients suffering from heart conditions.

Westlake Therapeutics is a biopharmaceutical company based in Hangzhou, China, founded in 2019. The company specializes in cell therapy, focusing on developing innovative treatments for rare diseases, cancer, and various immunological and metabolic disorders. Central to its approach is the REDx platform, which utilizes engineered red blood cell technology. This platform enables the genetic engineering of hematopoietic stem and progenitor cells sourced from peripheral blood, bone marrow, or cord blood. By leveraging this technology, Westlake Therapeutics aims to create personalized therapies that enhance treatment options for patients facing a wide range of health challenges.

Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in biotechnology. It specializes in antibody-based drugs that enhance immune system function, along with providing technical consultation and drug quality inspection services. By focusing on these areas, Kanova aims to help clients improve drug quality and advance the discovery of new biomedicine efficiently.

Reliable Med is a developer and provider of clinical mass spectrometry equipment designed for in vitro diagnostic (IVD) tests. The company focuses on addressing the needs of the medical industry by offering high-end clinical mass spectrometry devices and IVD detection kits. By doing so, Reliable Med aims to enhance the efficiency and accuracy of patient diagnoses within the healthcare sector.

Matridx is a company based in Hangzhou, China, specializing in the development, production, and sales of molecular diagnostic products aimed at infectious diseases. The company offers PDC-Seq, a technology that enables high-throughput sequencing of nucleic acids from samples collected from infected patients. Matridx utilizes advanced molecular technologies, including gene editing techniques and high-throughput sequencing, to create reliable genetic testing solutions. The company's focus is on simplifying, accelerating, and enhancing the diagnostic process for infectious pathogens, ultimately supporting major medical companies in their diagnostic efforts.

SeekGene specializes in genetic data analysis solutions, particularly in the development and clinical application of single-cell sorting assays. The company leverages its extensive research and clinical service experience to advance single-cell sequencing technology for real-world clinical research. SeekGene has developed a high-throughput single-cell transcriptome sequencing kit that is recognized for its superior performance, flexibility, and cost-effectiveness. This technology aims to facilitate the clinical transformation of single-cell sequencing, enabling better understanding of immune responses at the single-cell level. Additionally, SeekGene focuses on T cell receptor and peptide-bound major histocompatibility complex pairing technologies, which are essential for clinical and drug research, as well as for monitoring and treating various diseases.

MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development and production of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, and metabolic disorders. The company offers a diverse range of products, including 45 innovative genetic metabolic disease screening reagents, deaf genetic testing kits, and HLA-B27 detection kits. These products aim to facilitate early detection of genetic conditions and birth defects, promoting timely intervention and disease prevention. Yingsheng Bio utilizes advanced molecular diagnostic techniques and sophisticated detection systems, contributing significantly to the fields of human genetics and public health.

Hugo Biotech is a developer of advanced microbial sequencing technology, specializing in high-throughput sequencing and genomic analysis. The company has sequenced nearly 20,000 clinical samples for over 300 leading hospitals in China. Its innovative approach allows for the rapid and precise identification of pathogenic microorganisms in clinical samples, eliminating the need for traditional culturing methods and specific amplification techniques. This capability supports healthcare professionals in making timely and informed decisions regarding patient treatment.

Matridx is a company based in Hangzhou, China, specializing in the development, production, and sales of molecular diagnostic products aimed at infectious diseases. The company offers PDC-Seq, a technology that enables high-throughput sequencing of nucleic acids from samples collected from infected patients. Matridx utilizes advanced molecular technologies, including gene editing techniques and high-throughput sequencing, to create reliable genetic testing solutions. The company's focus is on simplifying, accelerating, and enhancing the diagnostic process for infectious pathogens, ultimately supporting major medical companies in their diagnostic efforts.

Shanghai Bioheart Biotechnology Co., Ltd., established in 2014 and located in Shanghai, China, specializes in the development of drug-eluting stents. The company is focused on creating innovative, high-value minimally invasive therapeutic products. Bioheart aims to enhance medical technology and provide superior healthcare solutions for medical professionals and patients alike, positioning itself as a significant player in the medical and healthcare industry.

HuidaGene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of gene therapies for single-gene disorders and is expanding its focus to neurodegenerative diseases and vision disorders. HuidaGene employs its proprietary CRISPR-based and AI-driven HG-PRECISE platform to create potentially curative therapies. Among its clinical programs, HuidaGene is advancing HG004 for RPE65-associated retinal disease, HG202 for neovascular age-related macular degeneration, HG204 for MECP2 duplication syndrome, and HG302 for Duchenne muscular dystrophy. Several of these therapies have received orphan drug designations and rare pediatric disease designations from regulatory authorities. In addition to its clinical initiatives, the company is exploring preclinical programs, including HG303 for amyotrophic lateral sclerosis and a CRISPR RNA-editing therapy for Alzheimer’s disease.

Shanghai Bioheart Biotechnology Co., Ltd., established in 2014 and located in Shanghai, China, specializes in the development of drug-eluting stents. The company is focused on creating innovative, high-value minimally invasive therapeutic products. Bioheart aims to enhance medical technology and provide superior healthcare solutions for medical professionals and patients alike, positioning itself as a significant player in the medical and healthcare industry.

Xinzhi Medical is a Shanghai-based cardiovascular interventional therapy device developer.Xinzhi Medical is committed to promoting the technical innovation of cardiovascular interventional therapy and developing interventional non-implanted products in cardiovascular field continuously.

Pulse Medical is a manufacturer specializing in cardiovascular interventional devices, focusing on the research, development, production, and sales of medical devices for cardiovascular care. The company offers a range of products, including wearable ECG monitoring equipment, extracorporeal shock wave therapy devices, and advanced imaging detectors for cardiac motion and full-body assessments. Based in Zhuhai, Guangdong, Pulse Medical benefits from government support and the expertise of both domestic and international specialists, which has contributed to its growth and innovation in the cardiovascular medical industry. The company's devices are designed to assist healthcare professionals in treating patients with chronic cardiovascular conditions efficiently and effectively.

Creative Biosciences is a biomedical technology company focused on developing and producing diagnostic products for tumor screening, particularly in the realm of colorectal cancer. The company specializes in fecal DNA detection technology, providing non-invasive screening kits that allow medical practitioners to accurately identify genetic abnormalities in fecal samples. These diagnostic tools are designed to aid in the early detection of intestinal cancer lesions, thereby supporting healthcare professionals and researchers in their efforts to improve cancer treatment outcomes. Through its innovative approach, Creative Biosciences aims to enhance cancer screening processes and contribute to better patient care.

Accunome is a company specializing in molecular diagnostic technology, focusing on the development of diagnostic instruments and detection reagents. It emphasizes research and development to enhance diagnostic efficiency and reduce costs for clients in the healthcare sector. Accunome has received state food and drug registration and EU CE certifications for its diagnostic platform, DXcellence12, as well as for its combined detection kit for influenza A/B and respiratory syncytial virus nucleic acid. Through its innovative solutions, the company aims to facilitate the diagnosis of severe infectious diseases.

Cellula is a medical and health company that provides IVD products. It is engaged in the field of reproductive health and provides integrated and cost-effective IVD products. They combine clinical needs to provide patients with accurate detection solutions and to provide inspectors with more convenient and technical products.

Urotronic, Inc. is a medical device company based in Plymouth, Minnesota, that specializes in developing innovative solutions for urology. Founded in 2014, the company focuses on its flagship product, Optilume, a drug-coated balloon (DCB) catheter designed to treat urethral strictures in men. This minimally invasive device combines balloon dilation with localized drug delivery, utilizing paclitaxel to prevent the recurrence of strictures by limiting cell proliferation and fibrotic scar tissue formation. Urotronic aims to provide urologists and patients with a cost-effective alternative to traditional treatment methods, improving outcomes for individuals suffering from urinary tract conditions.

Quiknos creates the ability to combine mobile Internet with medical cold chain logistics and enters the market for medical services from the space of clinical medical examination, offering medical institutions services linked to platform software and medical cold chain transportation. They use complete medical cold chain logistics and information technology to assist grassroots doctors in improving their diagnosis and treatment levels. By enabling community-based medical institutions, quick and simple checks encourage the distribution of medical resources and make medical services accessible.

Ningbo Jenscare Scientific develops solutions around structural heart disease that include the treatment of the tricuspid valve, mitral valve, aortic valve, and heart failure. The company's contact information is its physical address.

CMAB BioPharm is a biopharmaceutical service firm based in Suzhou, China, specializing in process development and manufacturing services for biologic products. Established in 2017, the company offers customized development and manufacturing solutions for antibodies and biologics, catering to both domestic and international clients. CMAB BioPharm's services include process development, GMP manufacturing, and the production of aseptic drug products, adhering to stringent quality standards. The firm supports its customers through all stages of drug development, providing comprehensive solutions for preclinical and clinical phases, from initial DNA sequences to commercial production.

12 Sigma Technologies, founded in April 2015, specializes in modern medical image diagnosis and medical data analysis, leveraging advanced artificial intelligence technology. The company focuses on the integration of medical imaging and AI, recognizing the substantial potential in this combination for enhancing diagnostic capabilities. To advance its offerings, 12 Sigma has established partnerships with General Electric to co-develop smart diagnostic products aimed at addressing conditions such as tumors and cardiovascular diseases. Additionally, the company collaborates with over 50 leading hospitals in China to conduct applied medical diagnostics, technical research, and clinical trials, positioning itself as a key player in the healthcare technology sector.

Shanghai Smartee Denti-Technology Co. Ltd is a company specializing in the development of an invisible orthodontic system, including a transparent aligner designed to move teeth into the desired position with precision. Founded in 2004 by a team of experts, including those with international experience and renowned orthodontics professionals, the company operates from the Shanghai Zhangjiang Hi-Tech Park. Smartee integrates advanced technologies such as 3D printing, computer-aided design (CAD), and digital modeling (CAM) to create aligners that are free from arch wires and brackets, making them safe for the oral cavity and easy to remove for eating and hygiene. The company collaborates with prominent research institutions, leveraging their expertise to enhance its digital orthodontic technology and has developed proprietary invisible appliance technology, which has received national accolades and patent protection for its innovative approach in orthodontics.

Creative Biosciences is a biomedical technology company focused on developing and producing diagnostic products for tumor screening, particularly in the realm of colorectal cancer. The company specializes in fecal DNA detection technology, providing non-invasive screening kits that allow medical practitioners to accurately identify genetic abnormalities in fecal samples. These diagnostic tools are designed to aid in the early detection of intestinal cancer lesions, thereby supporting healthcare professionals and researchers in their efforts to improve cancer treatment outcomes. Through its innovative approach, Creative Biosciences aims to enhance cancer screening processes and contribute to better patient care.

Microread is a commercialization company that focuses on sequencing technology platforms for genetic detection. They refined production processes and quality verification, and they developed a series of economical test reagents for forensic, clinical, agricultural, animal husbandry, and research fields.

Wallaby Medical is a manufacturing company that produces Avenir coil systems and medical devices for stroke treatment.

MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.

MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.

Singlera Genomics Inc. specializes in genetic testing and molecular diagnostic technologies, focusing on non-invasive solutions for cancer screening and diagnosis. The company has developed a methylation detection platform that aids in early tumor detection and cancer prevention. Its offerings include tumor diagnosis, personalized treatment options, non-invasive prenatal diagnosis, and pre-implantation genetic screening, along with customized scientific research services. Founded in 2014 and based in La Jolla, California, Singlera also operates research and development centers in Shanghai, China, and is committed to advancing precision medicine to provide patients with early, accurate, and informative diagnoses.

SinoVision is a medical device manufacturing company based in China, established in 2012. It specializes in the development of computed tomography (CT) scanners, offering a range of products including 16-Slice, 32-Slice, and 64-Slice CT scanners. The company also provides advanced technologies such as the sROBOT robot CT navigation system and sAI intelligent imaging solutions. SinoVision holds intellectual property for CT detectors and designs X-ray tubes and high-voltage power supplies specifically for CT scanners. Additionally, it operates a cloud diagnosis platform that integrates CT image post-processing workstations with an online consultation platform, facilitating comprehensive imaging diagnoses for healthcare professionals and institutions.

Quiknos creates the ability to combine mobile Internet with medical cold chain logistics and enters the market for medical services from the space of clinical medical examination, offering medical institutions services linked to platform software and medical cold chain transportation. They use complete medical cold chain logistics and information technology to assist grassroots doctors in improving their diagnosis and treatment levels. By enabling community-based medical institutions, quick and simple checks encourage the distribution of medical resources and make medical services accessible.

Percutek Therapeutics specializes in the research, development, and manufacturing of cardiovascular interventional medical devices. The company focuses on Class III minimally invasive devices aimed at diagnosing and treating a range of cardiovascular conditions. Its product portfolio includes devices for various applications, such as aortic, peripheral, and coronary interventions, as well as nerve access. By prioritizing patient safety and clinical efficacy, Percutek Therapeutics is committed to delivering high-quality solutions that enhance the treatment of vascular diseases, thereby supporting both healthcare providers and patients in achieving better health outcomes.

Jiangsu Superbio Life Science Co., Ltd, founded in 2011 and based in Nanjing, China, specializes in gene sequencing and laboratory testing services. The company provides a range of services that include forensic and third-party medical testing, focusing on judicial and medical applications. Superbio utilizes advanced technology platforms, such as biochip technology, automated instruments, bioinformatics, and genetic engineering, to deliver its services. Its gene sequencing technology is particularly significant in forensic contexts, aiding in medical and legal disputes. Additionally, the company offers testing services related to food and drug safety, along with specialized services like paternity testing and forensic pathology identification, thereby catering to diverse client needs in the fields of health and law.

Righton is a Shanghai-based biotechnology company specializing in genetic engineering and the development of in vitro diagnostic products. The company focuses on researching and producing molecular diagnostic reagent kits, offering comprehensive scientific research and testing services. Righton aims to advance the field of molecular diagnostics through innovative solutions that enhance medical testing and diagnostics capabilities.

SinoVision is a medical device manufacturing company based in China, established in 2012. It specializes in the development of computed tomography (CT) scanners, offering a range of products including 16-Slice, 32-Slice, and 64-Slice CT scanners. The company also provides advanced technologies such as the sROBOT robot CT navigation system and sAI intelligent imaging solutions. SinoVision holds intellectual property for CT detectors and designs X-ray tubes and high-voltage power supplies specifically for CT scanners. Additionally, it operates a cloud diagnosis platform that integrates CT image post-processing workstations with an online consultation platform, facilitating comprehensive imaging diagnoses for healthcare professionals and institutions.

Med Lighter, founded in 2014 and based in Beijing, China, specializes in developing a comprehensive learning and communication platform for medical professionals. The company offers an application that provides extensive medical imaging information across various body parts, utilizing modalities such as MRI, CT, X-ray, and ultrasound. In addition to imaging data, the platform includes supplementary knowledge, such as blood supply areas, to enhance medical understanding. Med Lighter also functions as a multi-center clinical trial collaboration platform, facilitating clinical case sharing and aiding doctors in managing outpatient and inpatient medical records, thereby improving overall work efficiency.

Biomarker Technologies, established in 2009 and based in Beijing, China, specializes in comprehensive genomic services that integrate scientific research with medical technology. The company offers a range of services, including gene sequencing, medical testing, and biological research, aimed at enhancing research capabilities for clients across various sectors. With a dedicated research and development team exceeding 500 members, Biomarker Technologies comprises highly educated professionals, including bioinformaticians, senior engineers, and experts from biotechnology, agriculture, medicine, and computing fields. This diverse expertise positions the company as a significant player in the genetic industry, committed to advancing scientific knowledge and medical applications.

SinoVision is a medical device manufacturing company based in China, established in 2012. It specializes in the development of computed tomography (CT) scanners, offering a range of products including 16-Slice, 32-Slice, and 64-Slice CT scanners. The company also provides advanced technologies such as the sROBOT robot CT navigation system and sAI intelligent imaging solutions. SinoVision holds intellectual property for CT detectors and designs X-ray tubes and high-voltage power supplies specifically for CT scanners. Additionally, it operates a cloud diagnosis platform that integrates CT image post-processing workstations with an online consultation platform, facilitating comprehensive imaging diagnoses for healthcare professionals and institutions.